Once valued at $6 billion, 23andMe has faced a series of setbacks that have severely impacted its market position. The ...

The restructuring arrives during a period of turmoil at California-based 23andMe, which has recently included a high-profile ...

NEW YORK — 23andMe is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts to slash costs. The ...